The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health

Inclusion Criteria:

* Males and females aged 50 to 75 years
* Participants who meet the requirements of a sedentary lifestyle. Meaning, subjects who do not meet the World Health Organization's (WHO) minimum activity guidelines, of at least 150 minutes of moderate-intensity activity, or, 75 minutes of vigorous-intensity activity a week, plus muscle-strengthening activities at least 2 days per week. Of importance, incidental physical activity (eg, walking to work, household activities) would not meet the standard of being physically active according to WHO guidelines (McKay et al., 2021).
* BMI of \> or equal to 25.00kg/m²
* Individuals with \> or equal to 5 score relative to high risk for prediabetes as defined by the CDC (https://www.cdc.gov/prediabetes/takethetest)
* Free of all other chronic diseases.
* Not currently using glucose-lowering agents or insulin.
* Able to read and write in English
* Willing to maintain a habitual diet, supplement routine, and avoid other lifestyle changes during the study period.
* During the study, participants agree not to take any other supplement that can impact glucose or insulin regulation.
* During the study, participants agree not to take any other supplement that can impact cardiovascular health, inflammatory status, or anti-aging supplements
* Willing to have blood drawn
* Must have access to a reliable internet connection and a computer to complete remote assessments

Exclusion Criteria:

* Unwilling to have blood drawn
* Unwilling to swallow pills
* Pregnancy or has breast fed within 3 months prior to enrollment
* Current use of prescription medication or drug that impacts Glucose or Insulin metabolism (including direct insulin treatment) within the past 6-months
* Current use of Quercetine or CoQ10 supplements within the past 4-weeks
* History or current alcohol or drug abuse
* Known diagnosis of any chronic cardiovascular, metabolic, endocrine, or renal disease outside of prediabetes as listed above.
* Has significant concurrent illnesses (controlled or uncontrolled), such as lupus, hepatitis B/C, HIV, serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in the past two years, or other conditions, which in the opinion of the investigator, such condition might be aggravated as a result of treatment
* Developmental disability or cognitive impairment that would preclude adequate comprehension of the informed consent form and/or ability to follow study subject requirements and/or record the necessary study measurements.
* History of cardiovascular disease (i.e., myocardial infarction, hypertension, hypercholesterolemia, peripheral vascular disease, other)
* History of neurological disorders (Parkinson's, Amyotrophic lateral sclerosis, epilepsy, spinal cord injury resulting in inability to use upper extremities, other.)
* History of gastrointestinal disorders that could lead to uncertain absorption of the study supplements (i.e., inflammatory bowel disease, ulcerative colitis, -Crohn's disease, colostomy, or eating disorder)
* History of kidney or liver disease
* History of metabolic disorders (diabetes, metabolic syndrome, other)
* History of current malignancy/cancer
* Receiving chemotherapy agents or radiation treatments
* Diagnosis of a terminal illness
* The investigator feels that, for any reason, the subject is not eligible to participate in the study